Get the Stockscreener App
0.3585
8.94%
-0.0352
Pre-market:
.36
0.0015
+0.42%
Cel-Sci Corp. Stock (CVM) Latest News
CEL-SCI advances Multikine study for head and neck cancer - Investing.com
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com
Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - StockTitan
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter
Breakthrough Cancer Treatment Shows 73% Survival Rate: CEL-SCI's Latest Clinical Milestone - StockTitan
CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World
Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA
Cel-Sci: Fiscal Q1 Earnings Snapshot -February 14, 2025 at 04:25 pm EST - Marketscreener.com
CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World
CVM: Fiscal Year 2024 Results - Research Tree
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Personal Finance - Business Wire
Short Interest in DoubleLine Income Solutions Fund (NYSE:DSL) Increases By 8.7% - Defense World
Have A Relaxing Holiday Season - MENAFN.COM
Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance
CEL-SCI's Multikine Shows 73% Survival Rate in Cancer Study, FDA Approves New Trial - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
CVM stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com Nigeria
Ithaka Group LLC Sells 913 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Hanlon Investment Management Inc. Purchases 405 Shares of Microsoft Co. (NASDAQ:MSFT) - Defense World
CEL-SCI Corporation (NYSE:CVM) Announces Completion of $5 Million OfferingOn December 31, 2024, CEL-SCI Corporation, a Colorado corporation, disclosed the successful closure of an offering valued at approximately $5,000,000. The offering involved t - Defense World
Cel-Sci Stock Slips After Public Offering: Retail's Neutral - MSN
CEL-SCI completes $5 million stock offering - Investing.com
CEL-SCI Announces Closing of $5 Million Offering - Yahoo Finance
8 things to know: Big Lots strikes deal to save hundreds of stores - The Business Journals
CEL-SCI Raises $5M to Advance Multikine Cancer Therapy Development Through Strategic Stock Offering - StockTitan
CVM Stock Hits 52-Week Low at $0.42 Amid Market Challenges - Investing.com Nigeria
SEC Form 424B5 filed by Cel-Sci Corporation - Quantisnow
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket - Benzinga
5 Stocks To Watch Heading Into Monday - MSN
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
CEL-SCI Announces Pricing of $5 Million Public Offering - Yahoo Finance
CEL-SCI Announces $5M Public Offering to Advance FDA-Designated Orphan Drug Multikine Cancer Therapy - StockTitan
CEL-SCI announces proposed public offering of common stock - MSN
CEL-SCI announces common stock offering, no amount given - MSN
CVMCel-Sci Corporation Latest Stock News & Market Updates - StockTitan
CEL-SCI Announces Proposed Public Offering of Common Stock - Yahoo Finance
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
CEL-SCI (CVM) Announces Public Offering to Advance Multikine Cancer Immunotherapy Development - StockTitan
Cancer Stocks in the Spotlight: The Immunotherapy Revolution - Baystreet.ca
CEL-SCI (NYSE:CVM) Trading Down 4.4% – Should You Sell? - Defense World
Have a Relaxing Holiday Season - Baystreet.ca
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):